Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iloperidone in Parkinson's Disease Psychosis
NCT05344365Phase 2Withdrawn
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Jun 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of iloperidone in Parkinson's disease (PD) (2 cohorts), sponsored by Vanda Pharmaceuticals Inc. Primary endpoints: Assessment of safety and tolerability of iloperidone at 5 weeks, Reduction in positive symptoms of Parkinson's disease psychosis at 5 weeks and 1 more. Planned start Jun 2022; status: withdrawn.
02
Drugs
iloperidone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05344365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05344365.